More manufacturers are embracing MAM, which simplifies biopharmaceutical product quality testing, and facilitates the measurement and monitoring of critical quality attributes.
In this interview with Biopharm International, Richard Rogers, principal scientist at Just Biotherapeutics and formerly a member of the Amgen team that developed and proved the concept behind MAM, describes the story behind the method, how it is moving from quality control testing into drug development, and how it is helping to guide new product and software development.
Read this article in BioPharm International's Outsourcing Resources 2019 eBook.
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 12–14
When referring to this article, please cite it as A. Shanley, "Using the Multiple Attribute Method for Process Development and Quality Control," BioPharm International's Outsourcing Resources eBook (April 2019).
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.